Insider Selling: Pharvaris (NASDAQ:PHVS) Director Sells $395,575.45 in Stock

Pharvaris N.V. (NASDAQ:PHVS) Director Viviane Monges sold 11,969 shares of the firm’s stock in a transaction dated Wednesday, September 23rd. The shares were sold at an average price of $33.05, for a total value of $395,575.45. Following the completion of the sale, the director directly owned 5,500 shares in the company, valued at $181,775. This trade represents a 68.52% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Pharvaris Price Performance

Pharvaris stock opened at $32.02 on Monday. The stock has a market cap of $2.09 billion, a PE ratio of -10.50 and a beta of -2.33. Pharvaris N.V. has a 12-month low of $20.65 and a 12-month high of $43.25. The business’s 50-day moving average price is $35.29 and its two-hundred day moving average price is $32.02.

Pharvaris (NASDAQ:PHVS) last posted its earnings results on Wednesday, August 12th. The company reported ($0.81) EPS for the quarter, missing analysts’ consensus estimates of ($0.75) by ($0.06). As a group, analysts expect that Pharvaris N.V. will post -3.12 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of PHVS. Quantbot Technologies LP acquired a new stake in shares of Pharvaris during the second quarter worth $41,000. CoreCap Advisors LLC acquired a new position in Pharvaris in the second quarter valued at $93,000. Public Employees Retirement System of Ohio bought a new stake in Pharvaris during the second quarter valued at $196,000. Algert Global LLC bought a new stake in Pharvaris during the second quarter valued at $238,000. Finally, Persistent Asset Partners Ltd acquired a new stake in Pharvaris during the 2nd quarter worth about $273,000.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on the stock. Rosenblatt Securities set a $60.00 target price on shares of Pharvaris in a research report on Wednesday, September 9th. Royal Bank Of Canada raised their price objective on Pharvaris from $52.00 to $62.00 and gave the company an “outperform” rating in a report on Wednesday, September 9th. Morgan Stanley upped their target price on Pharvaris from $46.00 to $62.00 and gave the stock an “overweight” rating in a report on Wednesday, September 9th. Citigroup reissued a “market outperform” rating on shares of Pharvaris in a research note on Wednesday, September 9th. Finally, Guggenheim upped their price objective on Pharvaris from $40.00 to $44.00 and gave the company a “buy” rating in a research note on Thursday, September 10th. Thirteen analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Pharvaris presently has a consensus rating of “Moderate Buy” and a consensus target price of $59.87.

About Pharvaris

Pharvaris N.V. is a biopharmaceutical company focused on developing oral therapies for hereditary angioedema (HAE), a rare genetic disorder characterized by recurrent episodes of swelling. The company is headquartered in Zug, Switzerland, and was founded in 2015 by former executives from Pharming Group.

Pharvaris’ lead investigational medicine is deucrictibant, an orally administered small-molecule bradykinin B2 receptor antagonist. The company is evaluating different formulations of deucrictibant for both on-demand treatment of HAE attacks and long-term prevention of attacks.